Human calcitonin. V. Synthesis and characterization of the protected calcitonin M-(1-10)-decapeptide

The present report describes in detail the synthesis and characterisation of the protected Calcitonin M decapeptide 1–10, , a key intermediate in the synthesis of Calcitonin M. I. was obtained from the openchain precursor Boc-Cys (Trt)-Gly-Asn-Leu-Ser (But)-Thr (But)-Cys (Trt)-Met-Leu-Gly-OH (II) by oxidation with iodine in a yield of 70%, after purification by counter-current distribution. II was prepared by fragment coupling of the sequences 1–4 and 5–10. The free calcitonin M (1–10)-decapeptide, obtained from I by removal of the protecting groups by acidolysis, has no hypocalcaemic activity and does not inhibit specific binding of calcitonin M to its antibodies in rabbit serum.     

Synthesis of salmon calcitonin, a high activity hypocalcemic hormone

A total synthesis of salmon calcitonin is described. The C-terminal nonapeptide amide 24–32 was coupled with the heptapeptide 17–23. The resulting hexadecapeptide amide 17–32 was reacted with the heptapeptide 10–16 to give the tricosapeptide 10–32. This was condensed with the N-terminal nonapeptide 1–9, yielding the protected dotriacontapeptide amide 1–32. After removal of the protective groups and purification by gel-filtration the free peptide obtained exhibited the physical, chemical and biological properties of the natural hormone. Its hypocalcaemic activity (ca. 3500 MRC U/mg) is 20–30 times higher than that of porcine or human calcitonin.     

Synthesis of thyrocalcitonin

A total synthesis of hog thyrocalcitonin is described. A protected C-terminal tridecapeptide amid (20–32) was coupled with a protected central decapeptide (10–19), and the resulting protected tricosapeptide amide (10–32) was reacted with the N-terminal protected nonapeptide (1–9). After elimination of the protective groups, a free dotriacontapeptide amide was obtained whose physical, chemical and biological behaviour was indistinguishable from that of the natural hormone.     

Human calcitonin. IV. Synthesis of calcitonin M

A preliminary account is giver of the synthesis of calcitonin M (I), isolated from human C-cell tumour tissue [2] [3]. Identity of the synthetic and the natural hormone was established by thin-layer chromatography, thin-layer electrophoresis and conversion to oxidation products, as well as by reference to the pattern of tryptic degradation and by comparing the biological activity of the two hormones. The findings also afforded additional confirmation of the results of structural elucidation [1]. In the synthesis of I, use was made of methods described previously [4] for the preparation of porcine α-thyrocalcitonin, and also of a new method [5] which easily permits the formation of cyclic cystine peptides.     

Synthesis of highly active corticotropic (1-D-serine,17,18-dilysine)-beta-corticotropin-(1-18)-octadecapeptide amide

A synthesis is described of [1-D -serine, 17, 18-dilysine]-β-corticotropin-(1–18)-octadecapeptide amide (I), a short chain ACTH analogue which has been found to possess in animals and also in man high and prolonged corticotropic activity. Synthesis was carried out by the fragment condensation approach involving, in the last build-up step, coupling of the protected sequences 1–10 and 11–18. From the protected octadecapeptide derivative 1–18 the free peptide was obtained in high yield by acidolysis.     

Human calcitonin. Structure of calcitonin M and D

Human calcitonin M and its dimer calcitonin D, two highly active peptides isolated from C cell tumours, were subjected to sequence studies using chemical and enzymatic methods. For calcitonin M, containing 32 amino acid residues, the following structure was derived: Though the disulphide bridge between position 1 and 7, and the C-terminal proline amide of human calcitonin M are the same as in porcine α-thyrocalcitonin, many amino acid residues - 18 in all - are different throughout the molecule. Arginine and tryptophan are absent; on the other hand, lysine and isoleucine are to be found at position 18 and 27 respectively. Methionine changes its place from position 25 to 8 adjacent to the disulphide bridge. Experimental evidence indicates that calcitonin D represents the antiparallel dimeer of calcitonin M.     

Human calcitonin. I. Isolation and characterization

Two highly active calcitonin peptides, M with 32 amino acids, and D a dimer of M, were isolated from a large human mediastinal C cell tumour. D can easily be transformed into M by the action of 1N ammonia; D and M afford two different sulphoxides, but all four peptides yield the same product upon oxidation with performic acid. Both D and M have a potency of about 120 MRC units/mg dry weight; their sulphoxides, by contrast, are almost inactive. Tryptic digestion of M produces an N-terminal octadecapeptide (Tr_I) and a C-terminal tetradecapeptide (Tr_II), the latter being also obtained from D. Amino acid analysis and other analytical data are presented. The structure of the human calcitonin peptides D and M is thus very different from that of porcine α-thyrocalcitonin.     

Synthese von Humaninsulin. II. Aufbau des cyclischen Fragments A(1–13)

Synthesis of human insulin. II. Preparation of the A(1–13) fragment. The present report gives a detailed account of the synthesis of the protected tridecapeptide A(1–13), Boc? Gly? Ile? Val? Glu(OBu^t)? Gln Ser(Bu^t)? Leu? OH ( 20 ), an essential intermediate in the recently published total synthesis of human insulin [1]. The main feature in the synthesis of 20 was the specific formation of a disulfide bond between A6 and A11 in the presence of an additional cysteine residue (A7). The selective ring closure was accomplished with the segment A(6–13), H? Cys(Trt)? Cys(Acm)? Thr(Bu^t)? Ser(Bu^t)? Ile? Cys(Trt)? Ser(Bu^t)? Leu? OH ( 18 ), which was obtained by way of conventional synthesis routes. Treatment of 18 with iodine in trifluoroethanol formed the desired disulfide bridge from the two S-trityl-cysteine residues without affecting the S-acetamidomethyl-protected cysteine A7. A final azide coupling with the N-terminal derivative A(1–5) ( 3 ) provided the tridecapeptide fragment 20 as a crystalline compound.     

A chiral synthesis of four stereoisomers of 1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline, an inducer of Parkinson-like syndrome

Four stereoisomers of 1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline, an inducer of Parkinson-like syndrome, were synthesized by applying a new method of 1,2,3,4-tetrahydroisoquinoline (TIQ) synthesis utilizing the Pummerer reaction as a key step. The chiral centers at C-1 and C-3 were constructed by two routes starting from alaninol (3) and 1-phenylethylamine (4) as a chiral source. Enantiomerically pure 1,3-dimethyl-TIQs (1R,3S)-(2) [corrected], (1S,3R)-(ent-2) [corrected], (1S,3S)-(1) [corrected], and (1R,3R)-(ent-1) [corrected] were prepared in a stereochemically unambiguous manner from 3 in 11 steps (route I) and from 4 in 6 steps (route II). The conformations of tetrahydroisoquinoline ring in 1-methyl, 3-methyl, and 1,3-dimethyl-TIQs were discussed on the basis of their CD, 1H-NMR spectra, and steric energies.     

Metal chelates in vinyl polymerization: Bulk polymerization of acrylonitrile initiated by Cu(II)–imine complexes

This article deals with the kinetics and mechanism of acrylonitrile (AN) polymerization initiated by Cu(II)–4-anilino 3-pentene 2-one[Cu(II)ANIPO], Cu(II)–4-p-toluedeno 3-pentene 2-one [Cu(II)TPO], and Cu(II)–4-p-nitroanilino 3-pentene 2-one [Cu(II)NAPO] in bulk at 60°C. The polymerization is free radical in nature. The exponent of initiator(I) is ? 0.5. The initiation step is a complex formation between the chelate and monomer and subsequent decomposition of the intermediate complex giving rise to free radical and Cu(I). This is substantiated by ultraviolet (UV) and electron spin resonance (ESR) studies. The activation energies and kinetic and chain transfer constants have also been evaluated.     

Synthesis of Pd(II) and Pt(II) complexes possessing bicyclo[3.2.0]heptanyl phosphinite ligands: Identification of a novel Pd(II) precatalyst for 1,6-diene cycloisomerisation

The synthesis of monodentate and bidentate phosphinite ligands, possessing the unusual bicyclo[3.2.0]heptane framework, are reported. A convenient, tin-free synthesis of a key intermediate, namely 3-endo-6-endo-dihydroxybicyclo[3.2.0]heptane, is described. The air-sensitive phosphinite ligand 1 was either protected as the borane adduct, which is air-stable, or reacted directly with bis(acetonitrile)palladium(II)chloride to give the novel air and moisture stable palladium(II) complex 11. A platinum(II) relative 12 has also been synthesised by reaction of phosphinite 1 with bis(benzonitrile)platinum(II)chloride. Each complex has been thoroughly characterised and their molecular structures confirmed by X-ray diffraction studies. In catalytic applications, such as cross-coupling reactions of organometallic reagents with organohalides, an unexpectedly poor activity has been established for 11. For example, Suzuki-Miyaura cross-coupling of activated and deactivated aryl bromides with aryl boronic acids, in the presence of catalytic quantities of 11, proceed in low yield, accompanied by substantial homocoupling. Palladium agglomeration, to produce catalytically inactive Pd black, is rapid in these reactions, under both aqueous and non-aqueous conditions. The poor reactivity is proposed to arise through an unfavourable near tetrahedral ‘(PP′)Pd(0)’ geometry, which slows the oxidative addition step in the catalytic cycle with either activated or deactivated aryl halides. The steric bulk of the ligand and the associated large P-M-P′ bite angle, particularly at the palladium zero oxidation state, is proposed to account for the poor reactivity. However, we have established that cationic derivatives of 11 promote the cycloisomerisation of diallylmalonate in a regioselective fashion.     

Tetraphosphinitoresorcinarene complexes: cationic silver(I) and copper(I) halide complexes as mercurate(II) anion receptors

The reactions of mercury(II) halides with the tetraphosphinitoresorcinarene complexes [P4M5X5], where M=Cu or Ag, X=Cl, Br, or I, and P4=(PhCH2CH2CHC6H2)4(O2CR)4(OPPh2)4 with R=C6H11, 4-C6H4Me, C4H3S, OCH2CCH, or OCH2Ph, have been studied. The reactions of the complexes with HgX2 when M=Ag and X=Cl or Br occur with elimination of silver(I) halide and formation of [P4Ag2X(HgX3)], but when M=Ag and X=I, the complexes [P4Ag4I5(HgI)] are formed. When M=Cu and X=I, the products were the remarkable capsule complexes [(P4Cu2I)2(Hg2X6)]. When M=Ag and X=I, the reaction with both CuI and HgI2 gave the complexes [P4Cu2I(Hg2I5)]. Many of these complexes are structurally characterized as containing mercurate anions weakly bonded to cationic tetraphosphinitoresorcinarene complexes of copper(I) or silver(I) in an unusual form of host-guest interaction. In contrast, the complex [P4Ag4I5(HgI)] is considered to be derived from an anionic silver cluster with an iodomercury(II) cation. Fluxionality of the complexes in solution is interpreted in terms of easy, reversible making and breaking of secondary bonds between the copper(I) or silver(I) cations and the mercurate anions.     

Synthesis and study of the biological activity of fragments of salmon calcitonin II

A number of fragments of salmon calcitonin II possessing analgesic activity of the nonopioid type have been synthesized.Institute of High-Molecular-Mass Compounds, Russian Academy of Sciences. Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg. Translated from Khimiya Prirodnykh Soedinenii, No. 1, pp. 126–132, January–February, 1993.     

Synthesis of human insulin. III. Preparation of the A(14-21) - B(17-30) fragment (author's transl)]

Synthesis of human insulin. III. Preparation of the A(14-21) - B(17-30) fragment. In the recently published total synthesis of human insulin [1], one of the three principal intermediates is the protected fragment in which sequence 14-21 of the A chain is linked to sequence 17-30 of the B chain by the disulfide bridge between A 20 and B 19. The synthesis of this fragment, and its characterization are described in detail in the present report. This open-chain asymmetrical cystine peptide was prepared by elongating the two chains in the already published intermediate first with fragment A(14–19), Bpoc-Tyr(Bu^t)-Gln-Leu-Glu(OBu^t)-Asn-Tyr(Bu^t)-NH-NH₂ (azide coupling), and secondly with fragment B(21–30), H-Glu(OBu^t)-Arg-Gly-Phe-Phe-Tyr(Bu^t)-Thr(Bu^t)-Pro-Lys(Boc)-Thr(Bu^t)-OBu^t (DCCI/HOBt).     

Unusual Course of the Reaction of Allyl Phosphine Oxides with the Grundmann Ketone

This article describes efficient preparation of isomeric allyl phosphine oxides possessing a protected cyclohexanediol fragment. Their base-catalyzed interconversions are examined and reactions with the Grundmann ketone provide an adduct containing the rearranged vinyl phosphine oxide moiety, instead of 19-norvitamin D₃ analogs, the expected products of the Horner–Wittig process.     

Studies on the synthesis of pectenotoxin II: synthesis of a C(11)-C(26) fragment precursor via [3 + 2]-annulation reactions of chiral allylsilanes

[see reaction]. A synthesis of tetracycle 2 corresponding to the C(11)-C(26) fragment of pectenotoxin II is described. The synthesis features two highly stereoselective [3 + 2]-annulation reactions of chiral allylsilanes, generated via allylboration of aldehydes with the chiral gamma-silylallylborane 4 or the gamma-silylallylboronate 19, for construction of the highly substituted C and E rings.     

Porphyrazines with annulated diazepine rings. 2. Alternative synthetic route to tetrakis-2,3-(5,7-diphenyl-1,4-diazepino)porphyrazines: new metal complexes, general physicochemical data, ultraviolet-visible linear and optical limiting behavior, and electrochemical and spectroelectrochemical properties

Following a previous report on the synthesis and physicochemical characterization of a novel class of porphyrazines carrying peripherally annulated seven-membered rings, i.e., tetrakis-2,3-(5,7-diphenyl-1,4-diazepino)porphyrazine [Ph(8)DzPzH(2)].4H(2)O and its metal derivatives [Ph(8)DzPzM].xH(2)O (x = 2-7, M = Mg(II)(H(2)O), Cu(II), and Zn(II)), a new more convenient procedure is reported here, allowing the preparation in high yields of the Li(I) and Na(I) derivatives of formulas [Ph(8)DzPzLi(2)].5H(2)O and [Ph(8)DzPzNa(2)].6H(2)O, which can be directly converted into other metal derivatives under mild conditions (room temperature) and in good yields. The series studied has been extended to include the Mn(II) and Co(II) complexes also reported here for the first time. Physicochemical characterization of the new "diazepinoporphyrazines" was based on fast atom bombardment (FAB) mass spectrometry and X-ray powder patterns, infrared (IR), electron paramagnetic resonance (EPR), and room-temperature magnetic susceptibility measurements. A detailed discussion of the UV-vis spectra emphasizes the role played by the external diazepine rings in electron delocalization through their tautomeric or protonated forms present in neutral, basic, and acidic media. The nonlinear optical effect of optical limiting for the different species [M = 2H, Mg(II)(H(2)O), Mn(II), Co(II), Cu(II), and Zn(II)] has also been measured. It has been observed that the extent of the optical limiting depends on the specific M center. The observed nonlinear optical features are analyzed and discussed in terms of the electronic and magnetic properties exhibited by some of the metal ions and taking into account the model of the excited-state absorption in which the nature of M determines the kinetics of formation of the highly absorbing state of the specific complex examined. As evidenced by the detailed electrochemical and spectroelectrochemical study carried out on this new class of macrocycles, one of the most important aspects is the facilitated electron delocalization for the oxidized and reduced species allowed by a 1H-6Htautomerism taking place on the peripheral diazepine rings.     

Stereoselective synthesis of CF(2)-substituted phosphothreonine mimetics and their incorporation into peptides using newly developed deprotection procedures

Stereoselective syntheses of all four stereoisomers of CF(2)-substituted nonhydrolyzable phosphothreonine derivatives (33, 39, and their enantiomers) and their incorporation into peptides are described herein. Key to the synthesis of these amino acids was construction of secondary phosphate-mimicking difluoromethylphosphonate units along with generation of two stereocenters. The former was achieved using a Cu(I)-mediated cross-coupling reaction of BrZnCF(2)P(O)(OEt)(2) (8) and beta-iodo-alpha,beta-unsaturated ester 12, with stereochemistry of both alpha- and beta-stereocenters being established using bornane-10,2-sultam as a chiral auxiliary. Diastereoselective hydrogenation of a chiral alpha,beta-unsaturated acylsultam (for the beta-center) (e.g., 16a) and subsequent stereoselective bromination (for the alpha-center of the threo derivative) or amination (for the alpha-center of erythro (allo) derivative) were utilized. Transesterification of the bromide to the benzyl ester followed by azide displacement of the halogen, then reduction of the resulting azide, followed by Boc-protection and finally removal of the benzyl group, afforded protected both L- and D-phosphothreonine mimetics (39 and its enantiomer). On the other hand, protected both L- and D-allo-phosphothreonine mimetics (33 and its enantiomer) were synthesized via transesterification of the above-mentioned amination product, followed by hydrogenolytic removal of the benzyl group. Key to utilization of these amino acid analogues in peptide synthesis was removal of ethyl protection from the difluoromethylphosphonate moiety. A two-step deprotection methodology, consisting of a combination of a first-step reagent [0.3 M BSTFA-TBAI in CH(2)Cl(2), BF(3).Et(2)O] followed by a second-step reagent [1 M TMSOTf-thioanisole in TFA, m-cresol, EDT] was developed for use in solid-phase protocols. A 12-residue Cdc (cell division cycle) 2-peptide 41, possessing two nonhydrolyzable phosphoamino acid mimetics (F(2)Pmab 6 and F(2)Pmp 4), was subjected to this deprotection procedure and was obtained in 25% yield based on the protected resin. The present synthetic method affords nonhydrolyzable phosphoamino acid mimetics-containing peptides in high yield without accompanying side reactions.     

Peptides-XXXIV: Synthesis of the 1–16 fragment of a lysozyme analogue

The synthesis of the 1–16 fragment of a lysozyme analogue is described. Three protected subfragments 1-4, 5-10 and 11-16 were combined using the N, N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide method. The fully protected hexadecapeptide was purified by gel filtration on Sephadex LH-60 eluting with N-methylpyrrolidone.